{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:40:26Z","timestamp":1760125226444,"version":"build-2065373602"},"reference-count":54,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural surface that includes three major histologic subtypes, epitheliod, sarcomatoid and biphasic. Epithelioid mesothelioma is usually associated with better prognosis. The genetic mechanisms driving MPM, the possible target mutations and the correlation with overall survival remain largely unsettled. We performed target exome sequencing in 29 cases of MPM aimed at identifying somatic mutations and, eventually, their correlation with phenotypic traits and prognostic significance. We found that KRAS mutations, occurring in 13.7% of cases, were associated with shortened median survival (7.6 versus 32.6 months in KRAS wild-type; p = 0.005), as it was the occurrence of any \u22653 mutations (7.6 versus 37.6 months; p = 0.049). Conversely, the presence of KDR single nucleotide polymorphism p.V297I (rs2305948) resulted in a favorable variable for survival (NR versus 23.4 months; p = 0.026). With the intrinsic limitations of a small number of cases and patient heterogeneity, results of this study contribute to the characterization of the mutation profile of MPM and the impact of selected somatic mutations, and possibly KDR polymorphism, on prognosis.<\/jats:p>","DOI":"10.3390\/cancers15072072","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T01:37:02Z","timestamp":1680226622000},"page":"2072","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"15","author":[{"given":"Margherita","family":"Vannucchi","sequence":"first","affiliation":[{"name":"Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Pennati","sequence":"additional","affiliation":[{"name":"Division of Pathological anatomy, Department of Medical and Surgical Critical Care, University of Florence, 50121 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clelia","family":"Mencaroni","sequence":"additional","affiliation":[{"name":"Division of Pathological anatomy, Department of Medical and Surgical Critical Care, University of Florence, 50121 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Defraia","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5946-8631","authenticated-orcid":false,"given":"Ledi","family":"Bardhi","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Castiglione","sequence":"additional","affiliation":[{"name":"Division of Pathological anatomy, Department of Medical and Surgical Critical Care, University of Florence, 50121 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-9007","authenticated-orcid":false,"given":"Cristiana","family":"Bellan","sequence":"additional","affiliation":[{"name":"Section of Pathology, Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla Eva","family":"Comin","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Section of Surgery, Histopathology and Molecular Pathology, University of Florence, 50121 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1016\/j.cllc.2020.05.020","article-title":"Clinical Features in Patients with Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses","volume":"21","author":"Paajanen","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Furuya, S., Chimed-Ochir, O., Takahashi, K., David, A., and Takala, J. (2018). Global Asbestos Disaster. Int. J. Environ. Res. Public Health, 15.","DOI":"10.20944\/preprints201804.0178.v1"},{"key":"ref_4","unstructured":"International Agency for Research on Cancer (1977). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Asbestos, International Agency for Research on Cancer."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: Advances since the 2015 classification","volume":"17","author":"Sauter","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Gaafar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","article-title":"Malignant pleural mesothelioma: Recent developments","volume":"33","author":"Sinn","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the Treatment of Malignant Pleural Mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5306\/wjco.v13.i4.267","article-title":"Tsunami of immunotherapy reaches mesothelioma","volume":"13","author":"Rosero","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bulcan.2017.11.007","article-title":"Molecular heterogeneity of malignant pleural mesotheliomas","volume":"105","author":"Tranchant","year":"2018","journal-title":"Bull. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Panou, V., and Roe, O.D. (2020). Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124327"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nymark, P., Lindholm, P.M., Korpela, M.V., Lahti, L., Ruosaari, S., Kaski, S., Hollmen, J., Anttila, S., Kinnula, V.L., and Knuutila, S. (2007). Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genom., 8.","DOI":"10.1186\/1471-2164-8-62"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","article-title":"The Molecular Basis of Malignant Pleural Mesothelioma","volume":"30","author":"Wadowski","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.18632\/oncotarget.7032","article-title":"Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas","volume":"7","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sato, T., and Sekido, Y. (2018). NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Iacono","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/carcin\/bgz087","article-title":"The lung-enriched p53 mutants V157F and R158L\/P regulate a gain of function transcriptome in lung cancer","volume":"41","author":"Barta","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s13277-013-1210-4","article-title":"The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: A review focused on the genes\u2019 molecular mechanisms","volume":"35","author":"Isoldi","year":"2014","journal-title":"Tumour. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1002\/jcp.26830","article-title":"Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas","volume":"233","author":"Sementino","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-018-1650-0","article-title":"p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification","volume":"16","author":"Tian","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jtho.2016.05.020","article-title":"The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing","volume":"11","author":"Hylebos","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pagano, M., Ceresoli, L., Zucali, P., Pasello, G., Garassino, M., Grosso, F., Tiseo, M., Parra, H.S., Zanelli, F., and Cappuzzo, F. (2020). Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers, 12.","DOI":"10.3390\/cancers12102948"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/17425247.2019.1598374","article-title":"Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma","volume":"16","author":"Chia","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jtho.2017.04.028","article-title":"Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib","volume":"12","author":"Agama","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2013.351","article-title":"Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma","volume":"33","author":"Tallet","year":"2014","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cakiroglu, E., and Senturk, S. (2020). Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176342"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41523-019-0110-1","article-title":"Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation","volume":"5","author":"Na","year":"2019","journal-title":"NPJ. Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2013.130","article-title":"Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma","volume":"108","author":"Mezzapelle","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/PDM.0b013e3182a3645e","article-title":"Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany","volume":"23","author":"Schildgen","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2014.08.004","article-title":"Identification of actionable mutations in malignant pleural mesothelioma","volume":"86","author":"Shukuya","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-018-0651-z","article-title":"Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Trassl, L., and Stathopoulos, G.T. (2022). KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player. Cancers, 14.","DOI":"10.3390\/cancers14174303"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e13631","DOI":"10.15252\/emmm.202013631","article-title":"KRAS signaling in malignant pleural mesothelioma","volume":"14","author":"Marazioti","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_47","first-page":"213","article-title":"The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid\/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion","volume":"21","author":"Duzkopru","year":"2017","journal-title":"Contemp. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"Hirayama","year":"2011","journal-title":"Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/0008-5472.CAN-08-3659","article-title":"The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells","volume":"69","author":"Catalano","year":"2009","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15330338211019433","DOI":"10.1177\/15330338211019433","article-title":"The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen","volume":"20","author":"Geng","year":"2021","journal-title":"Technol Cancer Res. Treat"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/IJGM.S300968","article-title":"Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment","volume":"14","author":"Bai","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1007\/s13277-014-2478-8","article-title":"Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma","volume":"35","author":"Zheng","year":"2014","journal-title":"Tumour. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/annonc\/mdw426","article-title":"Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation","volume":"27","author":"Tinhofer","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JTO.0b013e31811f3aab","article-title":"Ras pathway activation in malignant mesothelioma","volume":"2","author":"Patel","year":"2007","journal-title":"J. Thorac. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2072\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:07:33Z","timestamp":1760123253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15072072"],"URL":"https:\/\/doi.org\/10.3390\/cancers15072072","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}